Aug 09, 2017
1st Quarter FY 2018, Consolidated Results, 1st Quarter FY 2018, Consolidated Results
May 10, 2017
Ajanta Pharma Ltd. a specialty pharmaceutical formulation company reported today its performance for the 4th quarter and financial year ended 31st March 2017.
Jan 24, 2017
With this press release, we intend to clarify that there is no import alert by US FDA on our facility or any of our products approved by US FDA.
Jan 24, 2017
Ajanta Pharma (3rd Quarter & 9 Months, FY 2017 Consolidated Results)
Jan 09, 2017
Ajanta Pharma Announces US FDA Approval for Duloxetine Hydrochloride Delayed Release Capsules
Nov 02, 2016
Mumbai, India - Ajanta Pharma Limited, announces today US FDA* approval and launch of Amlodipine + Olmesartan Medoxomil Tablets in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc.
Oct 26, 2016
PAT up 26%, Income from Operations up 17% in Q2 FY 2017 (2nd Quarter & Half Year, FY 2017 Consolidated Results)
Sep 14, 2016
Ajanta Pharma Limited announces the receipt of final approval for Aripiprazole Tablets (2mg, 5mg, 10mg, 15mg, 20mg, 30mg), the bioequivalent generic to Abilify®1 from the US FDA*. Ajanta Pharma USA Inc, a whol
Jul 29, 2016
Ajanta Pharma Limited announces the receipt of final approval for Omeprazole and Sodium Bicarbonate Powder for Oral Suspension from US FDA*. It is a bioequivalent generic version of Zegerid®
Jul 26, 2016
Ajanta Pharma Ltd. a specialty focused pharmaceutical formulation company reported today its performance for the 1st quarter ended 30th June 2016.